Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck

Recchia, F.; Lalli, Angelo; Lombardo, Marco; Filippis, Sandro De; Saggio, Gaetano; Fabbri, Francesca; Rosselli, Michele; Capomolla, Elisabetta; Rea, Silvio

doi:10.1002/1097-0142(20010815)92:4<814::aid-cncr1387>3.0.co;2-8

Cited by 29 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequent studies demonstrated efficacy of 13- cis -RA treatment in cutaneous and cervical squamous cell carcinoma [23]. Phase I and II trials have also shown efficacy of 13- cis -RA in combination with chemotherapeutic agents [24] or interferon therapy [25] in the treatment of advanced head and neck squamous cell carcinoma. In the treatment of neuroblastoma, the initial studies of 13- cis -RA in children with advanced neuroblastoma failed to show efficacy in the face of active disease [26].…”

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Waters

Stewart

Atigadda

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Neuroblastoma remains a common cause of pediatric cancer deaths, especially for children who present with advanced stage or recurrent disease. Currently, retinoic acid therapy is used as maintenance treatment to induce differentiation and reduce tumor recurrence following induction therapy for neuroblastoma, but unavoidable side effects are seen. A novel retinoid, UAB30, has been shown to generate negligible toxicities. In the current study, we hypothesized that UAB30 would have a significant impact on multiple neuroblastoma cell lines in vitro and in vivo. Cellular survival, cell cycle analysis, migration, and invasion were studied using alamarBlue® assays, FACS, and Transwell® assays, respectively, in multiple cell lines following treatment with UAB30. In addition, an in vivo murine model of human neuroblastoma was utilized to study the effects of UAB30 upon tumor xenograft growth and animal survival. We successfully demonstrated decreased cellular survival, invasion and migration, cell cycle arrest and increased apoptosis after treatment with UAB30. Furthermore, inhibition of tumor growth and increased survival was observed in a murine neuroblastoma xenograft model. The results of these in vitro and in vivo studies suggest a potential therapeutic role for the low toxicity synthetic retinoid X receptor selective agonist, UAB30, in neuroblastoma treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Waters

Stewart

Atigadda

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…A phase III randomized trial did not confirm the results, as no prevention of tumor recurrence or second primary tumors were detected, possibly due to a lack of appropriate statistical power [66]. Nonrandomized trials of 13- cis -RA in combination with interferon-α2a and chemotherapy for the treatment of advanced head and neck cancers showed promising results, and are awaiting confirmation by randomized studies [67]. …”

Section: Medical Use Of Retinoids and Rexinoidsmentioning

confidence: 99%

Retinoids and rexinoids in cancer prevention: from laboratory to clinic

Uray

Dmitrovsky

Brown

2016

Seminars in Oncology

134

102

View full text Add to dashboard Cite

Early in the age of modern medicine the consequences of vitamin A deficiency drew attention to the fundamental link between retinoid-dependent homeostatic regulation and malignant hyperproliferative diseases. The term retinoid includes a handful of endogenous and a large group of synthetic derivatives of vitamin A. These multifunctional lipid-soluble compounds directly regulate target genes of specific biological functions and critical signaling pathways to orchestrate complex functions from vision to development, metabolism and inflammation. Many of the retinoid activities on the cellular level have been well characterized and translated to the regulation of processes like differentiation and cell death, which play critical roles in the outcome of malignant transformation of tissues. In fact, retinoid-based differentiation therapy of acute promyelocytic leukemia was one of the first successful examples of molecularly targeted treatment strategies. The selectivity, high receptor binding affinity and the ability of retinoids to directly modulate gene expression programs present a distinct pharmacological opportunity for cancer treatment and prevention. However, to fully exploit their potential, the adverse effects of retinoids must be averted. In this review we provide an overview of the biology of retinoid (activated by nuclear retinoic acid receptors, RARs) and rexinoid (engaged by nuclear retinoid X receptors, RXRs) action concluded from a long line of preclinical studies, in relation to normal and transformed states of cells. We will also discuss the past and current uses of retinoids in the treatment of malignancies, the potential of rexinoids in the cancer prevention setting, both as single agents and in combinations.

show abstract

“…[4][5][6] Multiagent combination regimens containing both retinoids and alkylating agents have been active in malignancies of several histologic subtypes. [7][8][9][10] On the basis of these observations, the North American Brain Tumor Consortium (NABTC) chose to perform a prospective, phase II, single-arm trial (NABTC 98 -03) of TMZ and cRA in patients with recurrent and progressive malignant gliomas.…”

Section: Espite Optimal Treatment For Malignant Gliomas Re-mentioning

confidence: 99%

“…[7][8][9][10] It was our hypothesis that the combination of TMZ and cRA would have therapeutic potential in glioma, based on observations of preclinical and clinical activity with each agent, different mechanisms of action, and predominantly nonoverlapping toxicity profiles.…”

mentioning

confidence: 99%

Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study

Jaeckle

Hess

Yung

et al. 2003

JCO

146

View full text Add to dashboard Cite

P h a s e I I E v a l u a t i o n o f T e m o z o l o m i d e a n d 1 3 -c i s -R e t i n o i c A c i d f o r t h e T r e a t m e n t o f R e c u r r e n t a n d P r o g r e s s i v e M a l i g n a n t G l i o m a : A N o r t h A m e r i c a n B r a i n T u m o r C o n s o r t i u m S t u d yMedian overall PFS was 19 weeks (95% CI, 16 to 27 weeks), and median overall survival (OS) was 47 weeks (95% CI, 36 to 58 weeks). OS was 46% (95% CI, 36% to 57%) at 52 weeks and 21% (95% CI, 13% to 31%) at 104 weeks. Of 84 assessable patients, there were two (3%) complete responses and eight (12%) partial responses (complete plus partial response, 15%). Among 499 treatment cycles, the most common grade 3/4 events included granulocytopenia (1.8%), thrombocytopenia (1.4%), and hypertriglyceridemia (1.2%).Conclusion: TMZ and cRA were active, exceeding our 20% thresholds for PFS 6 success, assuming 20% improvement over our previously reported database (glioblastoma multiforme: expected, 30%; observed, 32%; anaplastic glioma: expected, 40%; observed, 50%).

show abstract

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck

Cited by 29 publications

References 29 publications

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Retinoids and rexinoids in cancer prevention: from laboratory to clinic

Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study

Contact Info

Product

Resources

About